ALSO NOTED: Lentigen moves to Gaithersburg; Acorda prices shares; Cytheris releases data; and much more...

> Lentigen Corporation today announced the company is moving its corporate headquarters and manufacturing facilities from the University of Maryland Baltimore County TechCenter to a new 26,000 square-foot facility in Gaithersburg. Release

> Acorda Therapeutics has priced a share offering at $21.50. Report

> Cytheris released new data from a Phase I/II study designed to investigate the safety of Interleukin-7 therapy in chronically HIV-1 infected patients. Release

> Combimatrix won a $31.4 million judgment in its lawsuit against an insurer. Release

> Watson Pharmaceuticals says its NDA for the enlarged prostate drug silodosin has been accepted for filing by the FDA. Report

> The Ketek saga has opened a new chapter, with subpoenas and accusations and even threats. Report

> Want a preview of some "sobering" and "possibly a little alarming" market data? IMS Health gave preliminary figures on the state of the pharma industry to the Health Industry Group Purchasing Organization. Brace yourself: U.S. market growth for drugs grew by only 3.8 percent in 2007--the worst growth rate since 1961. Report

> Will a new Avastin-in-breast-cancer study persuade the FDA? Genentech hopes so. Report

> It's a new blow for the controversial painkiller fentanyl. Johnson & Johnson and Sandoz are recalling defective fentanyl patches that could cause patients or caregivers to overdose. Report

> A protein may hold the key to a new vaccine that could effectively target pneumonia, according to Children's Hospital of Pittsburgh of UPMC. Report

> In a first, Geron made headlines at the BIO CEO conference in New York with its announcement that it could begin its first human trials using embryonic stem cells to treat spinal cord injuries as early as this spring. Report

And Finally... Long after Sept. 11, 2001, Americans' terrorism-related thoughts and fears are associated with increased depression, anxiety, hostility, post-traumatic stress and drinking, University of Illinois at Chicago researchers have found. Release

Suggested Articles

Across its 15-year history, Omega Funds has a hand in a clutch of high-profile biotechs such as Editas Medicine and Juno Therapeutics.

After Novartis’ near $10 billion buyout of The Medicines Company, many thought cardiovascular therapies were hot again.

Mutations in RIPK1 can cause uncontrolled cell death and inflammation, researchers discovered by studying families with an autoimmune disorder.